Related Experiment Video

Updated: Jun 1, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Complement regulators as novel targets for anti-cancer therapy: A comprehensive review

Ruchi Saxena1, Elizabeth B Gottlin2, Michael J Campa2

  • 1Department of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.

Seminars in Immunology
|January 18, 2025
PubMed

Insights

The complement system, part of innate immunity, plays a dual role in cancer. Researchers are exploring complement regulators as potential targets for novel anti-cancer therapies.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Cancer treatment seeks advanced, personalized therapies beyond surgery, chemotherapy, and radiation.
  • Immunotherapy has emerged as a promising cancer treatment strategy.
  • The complement system, a key part of innate immunity, is increasingly recognized for its complex role in cancer.

Purpose of the Study:

  • To review the intricate role of complement regulators in cancer development and progression.
  • To examine complement regulators as potential therapeutic targets for cancer.
  • To discuss current strategies, challenges, and clinical research in targeting complement regulators for cancer therapy.

Main Methods:

  • Literature review of scientific articles and clinical research.
  • Analysis of the dual role of the complement system in cancer biology.
  • Examination of specific complement regulators (CD46, CD55, CD59, complement factor H) in the tumor microenvironment.

Main Results:

  • The complement system has a context-dependent role, potentially aiding immune surveillance or promoting tumor progression.
  • Complement regulators (CD46, CD55, CD59, complement factor H) are implicated in the tumor microenvironment.
  • These regulators offer potential therapeutic targets for novel anti-cancer strategies.

Conclusions:

  • Complement regulators represent a promising area for developing targeted cancer therapies.
  • Further research and clinical trials are needed to fully realize the therapeutic potential of targeting the complement system in cancer.
  • Understanding the complex interplay between complement regulators and cancer is crucial for advancing treatment options.
Keywords:
AntibodiesCD46CD55CD59CFH: complement factor HCancer therapyComplement: Complement regulatory proteins

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
468
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K